Daily Archives: September 19, 2014

New Xultophy® (IDegLira) Data Show Rapid and Predictable Glycaemic Improvements in People with Type 2 Diabetes

VIENNA, Sept. 19, 2014 /PRNewswire/ — Not intended for UK media Analyses of DUAL™ trial data compared Xultophy® (IDegLira)to insulin degludec and liraglutide alone in both insulin-naïve and insulin-treated patients…

ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results

VIENNA, Austria, Sept. 19, 2014 /PRNewswire/ — Reductions in kidney failure obtained during intensive glucose control persist for many years in people with diabetes type 2 "Intensive treatment is likely…

Blood Pressure Treatment Benefits on Survival Persist for Years – New Findings in Patients with Type 2 Diabetes

VIENNA, Sept. 19, 2014 /PRNewswire/ — Report from the European Society of Cardiology Congress – September 2014  Australian researchers have discovered that the reductions in heart events and death, from…

Merck Serono Awards Grant for Growth Innovation (GGI) for the First Time

DARMSTADT, Germany, September 19, 2014 /PRNewswire/ — The first grants awarded to coincide with the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative projects for the advancement…

Merck Strengthens Executive Board

DARMSTADT, Germany, September 19, 2014 /PRNewswire/ — Stefan Oschmann appointed Deputy CEO and Vice Chairman of the Executive Board Belen Garijo appointed new member of the Executive Board Changes effective…

Patient Engagement: Will the Holy Grail of Healthcare Clear the Hurdle?

— Frost & Sullivan challenges the perceived overkill from the popular buzzword at Health 2.0’s Fall Conference 2014, uncovering health IT solutions drawing patients to their care MOUNTAIN VIEW, California,…